Open Orphan (ORPH) CEO Cathal Friel joins Vox Markets for a Q&A session August 12, 2019 – Posted in: Open Orphan (ORPH)
Watch the interview here
Continue reading
Watch the interview here
Continue readingCathal Friel, Chief Executive Officer of Open Orphan (ORPH) talks about the appointment to the board of David Kelly as an Independent Non-Executive Director. Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to…
Continue readingOpen Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that Admission and dealings in its ordinary shares of 0.1 pence each (“Ordinary Shares”) on AIM and Euronext Growth Dublin will commence at 8.00 a.m. today under the ticker ORPH. Highlights The Company will target the fragmented orphan drug services market in Europe The orphan drug sector is one of the fastest growing sectors in the global pharmaceutical industry and in the US in 2018 over 50%…
Continue reading